Our store location is now open with huge sales on RUO products. Monday, Wednesday and Friday 11 a.m. to 6 p.m., Saturday 11 a.m. to 4 p.m.
Marvel Peptide USA
Cagrilintide

Cagrilintide

Supplied as a lyophilized powder in a sealed vial, for laboratory research use only.

$50.00 per vial

Strengths and prices

StrengthPrice per vial AvailabilityBatch
10 mg $50.00 In stock 20261023-L-B

Every vial carries its batch code and a QR that opens the certificate of analysis for that exact batch. No account is needed to read one.

What it is

Cagrilintide is a long-acting synthetic analogue of amylin, a hormone released with insulin by the pancreas. A fatty-acid side chain extends its half-life.

Identity

TypeSynthetic acylated peptide (amylin analogue)
Molecular formulaC194H312N54O59S2
Molecular weight4409 g/mol
CAS number1415456-99-3
PubChem CID171397054

Cagrilintide is a synthetic acylated peptide of 37 amino acids, Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH2, with a disulfide bridge between the cysteines at positions 2 and 7 and an amidated C-terminus, as in amylin. It differs from human amylin at six positions, among them prolines at 25, 28 and 29. The N-terminal lysine carries a 20-carbon fatty diacid (19-carboxynonadecanoyl) attached through a gamma-glutamyl linker, the side chain that extends its half-life. Molecular formula C194H312N54O59S2, molecular weight 4409 g/mol (PubChem CID 171397054, CAS 1415456-99-3). Mass spectrometry confirms the intact mass, including the disulfide and the side chain, and HPLC reports purity. It is supplied as a lyophilized powder in a sealed vial.

What the published research covers

Cagrilintide has been studied in phase 2 and phase 3 clinical trials of body weight, alone and combined with semaglutide. Results are published in peer-reviewed journals.

Cagrilintide was developed by Novo Nordisk as a long-acting analogue of amylin, a peptide hormone released from the pancreas together with insulin. Native amylin readily forms amyloid fibrils, which makes it difficult to develop as a drug, and the earlier analogue pramlintide has a short half-life. A 2021 paper described the structure-activity work that led to cagrilintide, a stable lipidated analogue selected for clinical development (Kruse, 2021).

Its human trials have measured body weight, alone and with the GLP-1 analogue semaglutide. A phase 1b trial in 96 otherwise healthy adults with overweight or obesity added escalating amounts of cagrilintide or placebo to semaglutide. Its primary endpoint was adverse events, about a third of which were gastrointestinal; the half-life of cagrilintide was 159 to 195 hours, and at week 20 the mean reduction in body weight was larger with the three highest cagrilintide amounts than with placebo (Enebo, 2021). A phase 2 trial assigned 706 adults without diabetes to one of five cagrilintide amounts, to liraglutide or to placebo; at 26 weeks mean body weight had fallen by 6.0% to 10.8% across the cagrilintide groups and by 3.0% with placebo, and gastrointestinal adverse events were more common with cagrilintide (Lau, 2021).

Phase 3 trials have tested the combination. In REDEFINE 1, 3,417 adults without diabetes were assigned to cagrilintide with semaglutide, semaglutide alone, cagrilintide alone or placebo for 68 weeks; the mean change in body weight was -20.4% with the combination and -3.0% with placebo, and gastrointestinal adverse events were reported by 79.6% and 39.9% of participants (Garvey, 2025). In REDEFINE 2, in 1,206 adults with type 2 diabetes, the corresponding changes were -13.7% and -3.4%, and 73.5% against 15.9% reached a glycated hemoglobin of 6.5% or less (Davies, 2025).

The trials were funded by the manufacturer, and the largest results concern the combination rather than cagrilintide alone. A New Drug Application for the combination was submitted to the FDA in December 2025, and no decision had been announced as of October 2026. The trials describe a pharmaceutical product made to its manufacturer's specifications, not this research material.

Regulatory status

Investigational as a single agent. Not approved by the FDA for any use. Supplied for laboratory research only.

Testing and documentation

Identity is confirmed by mass spectrometry and purity by HPLC. The certificate of analysis for the batch is reachable from the code on the vial.

Questions laboratories ask

What strengths is cagrilintide offered in?
Vials of 10 mg, as listed on the product page. The amount is on the vial label and on the certificate of analysis for the batch.
Is cagrilintide an approved drug?
No. Cagrilintide is investigational. A New Drug Application for cagrilintide combined with semaglutide was submitted to the FDA in December 2025, and no decision had been announced as of October 2026. This material is not approved by the FDA for any use and is supplied for laboratory research only.
How is a batch tested?
By an independent laboratory: identity by mass spectrometry and purity by HPLC. The QR code on the vial opens the certificate of analysis for that exact batch; no account is needed to read it.
Who can order, and how does it ship?
Orders are accepted under the Research Use Agreement, reaffirmed with every order. Orders ship from Montana, the next business day when paid by card, to United States addresses only and not to freight forwarders.

References

  1. Enebo LB et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. PubMed 33894838
  2. Kruse T et al. (2021). Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of Medicinal Chemistry. PubMed 34288673
  3. Lau DCW et al. (2021). Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. PubMed 34798060
  4. Garvey WT et al. (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. PubMed 40544433
  5. Davies MJ et al. (2025). Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. New England Journal of Medicine. PubMed 40544432

How it ships

Next day
Dispatched from Montana on all orders, packed and tracked.
One vial
The minimum order. You pay by card at checkout, or by invoice before the order ships.
Your batch
The certificate of analysis for the batch you receive is on the vial and on this site.

Ordering

Ordering needs an account. A retail account opens as soon as you request it and costs nothing. You pay by card at checkout, or by invoice before the order ships. A wholesale account is reviewed before it opens.

Research use only

This product is a research chemical sold solely for in-vitro laboratory research by qualified persons. It is not a drug, food, supplement or cosmetic, has not been evaluated by the FDA, and must not be administered to any person or animal. Read the full agreement

More from the catalog

All peptides, strengths and prices →